Clindamycin in the treatment of human ocular toxoplasmosis.
Clindamycin was used systemically and periocularly to treat six patients with ocular toxoplasmosis who had a total of eight attacks. Although it appeared to quiet the attack promptly, several side effects were noted. Transient diplopia occured after large periocular doses and papillitis resulted from retrobulbar administration. Despite its efficacy, the results do not seem to warrant high systemic doses for prolonged periods in view of its systemic toxicity. Clindamycin may be most useful as a periocular injection in moderate dosage. A controlled double-blind study is needed.
D000328:Adult; D002648:Child; D002981:Clindamycin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009898:Optic Disk; D009902:Optic Neuritis / Q000139:chemically induced; D014126:Toxoplasmosis, Ocular / Q000188:drug therapy*
D002981:Clindamycin